

under the terms of the Government in the Sunshine Act (5 U.S.C. 552b(c)(9)(B)).

Due to programmatic issues that had to be resolved, the **Federal Register** notice amendment is being published less than fifteen days before the date of the meeting.

FOR FURTHER INFORMATION CONTACT: Martha F. Katz, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE., Mailstop D-23, Atlanta, Georgia 30333, telephone 404/639-3243.

Dated: January 17, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-1590 Filed 1-20-95; 8:45 am]

BILLING CODE 4163-18-M

National Committee on Vital and Health Statistics (NCVHS), Subcommittee on Mental Health Statistics, and NCVHS Subcommittee on Disability and Long-Term Care Statistics; Meetings

Pursuant to Pub. L. 92-463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following subcommittee meetings.

Name: NCVHS Subcommittee on Mental Health Statistics.

Time and Date: 9 a.m.-12 noon, February 7, 1995.

Place: Room 303A-305A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Mental Health Statistics will review developments in managed care and assess their implications for enrollment and encounter data sets.

Name: NCVHS Subcommittee on Mental Health Statistics and NCVHS Subcommittee on Disability and Long-Term Care Statistics.

Time and Date: 1 p.m.-5 p.m., February 7, 1995.

Place: Room 303A-305A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Mental Health Statistics and the Subcommittee on Disability and Long-Term Care Statistics will meet jointly to consider disability and health care utilization items for enrollment and encounter data sets.

Name: NCVHS Subcommittee on Disability and Long-Term Care Statistics.

Time and Date: 9:30 a.m.-12:30 p.m., February 8, 1995.

Place: Room 303A-305A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Subcommittee on Disability and Long-Term Care Statistics will receive

presentations from staff of the Agency for Health Care Policy and Research on long-term care data in the National Medical Expenditure Survey.

FOR FURTHER INFORMATION CONTACT: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, room 1100, Presidential Building, 6265 Belcrest Road, Hyattsville, Maryland 20782, telephone 301/436-7050.

Dated: January 17, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-1589 Filed 1-20-95; 8:45 am]

BILLING CODE 4163-18-M

Board of Scientific Counselors, National Institute for Occupational Safety and Health; Meeting

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Times and Dates: 10 a.m.-4:30 p.m., February 7, 1995. 9 a.m.-3 p.m., February 8, 1995.

Place: The Washington Court Hotel, Ash Room, 525 New Jersey Avenue NW., Washington, DC 20001.

Status: Open to the public, limited only by space available.

Purpose: The board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: The agenda will include the NIOSH Director's report, along with a report from the Deputy Director; a legislative review; a review of recently funded extramural research programs; agricultural program review; construction program review; final disposition of research review and training review; toxicology review; and future activities of the Board of Scientific Counselors. Agenda items are subject to change as priorities dictate. This session will be opened to the public, being limited only by space available.

FOR FURTHER INFORMATION CONTACT: Richard A. Lemen, Ph.D., Executive Secretary, BSC, NIOSH, and Deputy Director, NIOSH, CDC, 1600 Clifton Road, NE., Mailstop D-35, Atlanta, Georgia 30333, telephone 404/639-3773.

Dated: January 17, 1995.

William H. Gimson,

Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-1697 Filed 1-20-95; 8:45 am]

BILLING CODE 4163-19-M

Public Health Service

Food and Drug Administration Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HF (Food and Drug Administration) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, and 56 FR 29484, June 27, 1991, as amended most recently in pertinent part 52 FR 34851, September 15, 1987) is amended to reflect an organizational change in the Food and Drug Administration (FDA).

The positions assigned to perform the centralized investigative activities located in the Division of Ethics and Program Integrity, Office of Management, Office of Management and Systems, FDA, will be transferred to the new Office of Internal Affairs within the Office of the Commissioner. The functions and staff associated with the activities will report directly to FDA's Deputy Commissioner/Senior Advisor in the Immediate Office of the Commissioner. Since these activities could involve investigations of alleged employee misconduct anywhere in the Agency and because of the importance of providing the FDA Commissioner with an early warning of any potential misconduct, the Deputy Commissioner/Senior Advisor to the Commissioner is the appropriate person to direct these activities. Functional statements of the newly established Office of Internal Affairs are identified below.

Under section HF-B, Organization:

1. Insert a new paragraph (a-5), *Office of Internal Affairs (HFA-G)* under the Office of the Commissioner (HFA) reading as follows:

Provides a centralized Agencywide investigative resource for the Commissioner, the Deputy Commissioners, and top Agency management.

Provides a centralized investigative liaison between FDA and the Office of the Inspector General (OIG).

Serves as an FDA investigative resource to conduct internal FDA investigations and to support OIG investigations.